Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 5/20 | 0.42 |
| ▸ | HTR1B | P28222 | 4/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.33 |
| ▸ | TOP2A | P11388 | 2/20 | 0.32 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26139843 | 0.93 | NISCH (0.40) | NOS3NOS1NOS2HTR1DHTR1B | |
| SCHEMBL26139841 | 0.91 | NISCH (0.39) | NOS3NOS1NOS2HTR1DHTR1B | |
| SCHEMBL1106435 | 0.85 | — | — | |
| SCHEMBL709292 | 0.80 | NOS3 (0.40) | NOS3NOS1NOS2HTR1DHTR1B | |
| SCHEMBL11708297 | 0.80 | NOS3 (0.40) | NOS3NOS1NOS2HTR1DHTR1B | |
| SCHEMBL709291 | 0.80 | NOS3 (0.40) | NOS3NOS1NOS2HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL226047 | 0.79 | NOS3 (0.39) | NOS3NOS1NOS2HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL3032314 | 0.79 | NOS3 (0.39) | NOS3NOS1NOS2HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL5186472 | 0.79 | NOS3 (0.39) | NOS3NOS1NOS2HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL226046 | 0.79 | NOS3 (0.39) | NOS3NOS1NOS2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0342742-A1 | Process for the preparation of 2-alkylpyrimidines | DowElanco (US) | 1989-11-23 | — | — | EP | claimed |
| JP-2017178-A | — | — | None | — | — | JP | disclosed |
| JP-59164757-A | — | — | None | — | — | JP | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-03-11 | — | — | US | disclosed |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-20180030034-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-01 | — | — | US | disclosed |
| JP-H0217178-A | PRODUCTION OF 2-ALKYLPYRIMIDINE | DOW CHEM | 1990-01-22 | — | — | JP | disclosed |
| EP-0342742-A1 | Process for the preparation of 2-alkylpyrimidines | DowElanco (US) | 1989-11-23 | — | — | EP | disclosed |
| US-4880929-A | OXIDATION, DEHYDRATION; OXIDATION CATALYSTS, METAL OXIDES, DIAMINOPROPANE WITH ACID | STAMICARBON B.V. (NL) | 1989-11-14 | — | — | US | disclosed |
| EP-0276503-A1 | Process for preparing a 2-alkyl- or 2-phenyl-1,4,5,6-tetrahydropyrimidineand and process for the preparation of 2-alkyl- or 2-phenyl- pyrimidines | DSM N.V. (NL) | 1988-08-03 | — | — | EP | disclosed |
| EP-0193973-B1 | METHOD OF PREPARATION OF 2-ALKYLPYRIMIDINE BY DEHYDROGENATION OF 2-ALKYLTETRAHYDROPYRIMIDINE | THE DOW CHEMICAL COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0193973-A1 | Method of preparation of 2-alkylpyrimidine by dehydrogenation of 2-alkyltetrahydropyrimidine | THE DOW CHEMICAL COMPANY (US) | 1986-09-10 | — | — | EP | disclosed |
| EP-0192297-A1 | Process for the preparation of A 2-alkylpyrimidine | STAMICARBON B.V. (NL) | 1986-08-27 | — | — | EP | disclosed |
| US-4493929-A | Preparation of 2-alkylpyrimidines | THE DOW CHEMICAL COMPANY (US) | 1985-01-15 | — | — | US | disclosed |
| JP-S59164757-A | NOVEL AMINOPROPYLPIVALAMIDES, MANUFACTURE AND USE FOR PRODUCING 2-TERTIARY-BUTYL-1,4,5,6-TETRAHYDROPYRIMIDINE | DOW CHEMICAL CO | 1984-09-17 | — | — | JP | disclosed |
| EP-0117882-A1 | Novel aminopropylpivalamides and a method of preparation | THE DOW CHEMICAL COMPANY (US) | 1984-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | SCN5A, PSMA5, API5 | NOS3 2474/4885NOS1 778/4885NOS2 2829/4885 |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | NOS3 2787/4885NOS1 2702/4885NOS2 3647/4885 |
| US-20180030034-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | NOS3 2787/4885NOS1 2702/4885NOS2 3647/4885 |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | KCNJ4, KCNK4, KCNQ4 | NOS3 2787/4885NOS1 2702/4885NOS2 3647/4885 |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | SCN5A, PSMA5, API5 | NOS3 2474/4885NOS1 778/4885NOS2 2829/4885 |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | NOS3 1959/4885NOS1 2407/4885NOS2 1974/4885 |
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | NOS3 4775/4885NOS1 4852/4885NOS2 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.